Canada Pharmaceutical Compliance

Discover OneScan

Global Regulations

Icon graphic element
Labelling

Products are required to display information in writing.

Summary

Pharmaceutical products in Canada are regulated by Health Canada under the Food and Drugs Act and the Food and Drug Regulations. Health Canada oversees the authorization, labeling, manufacturing, importation, and distribution of medicines to ensure product safety, quality, and efficacy.

Canada does not currently operate a national pharmaceutical serialization or track and trace system similar to those implemented in the United States, European Union, or several Middle East and CIS countries. Instead, regulatory oversight focuses on product authorization, good manufacturing practices, labeling compliance, and pharmacovigilance.

Canada has implemented drug identification and verification mechanisms, including the Drug Identification Number (DIN) and national drug product databases that allow regulators and healthcare professionals to verify approved medicines. Supply chain traceability is generally managed through industry systems and wholesale distribution records, rather than through a centralized regulatory serialization platform.

Labelling Requirements 

All medicines sold in Canada must comply with labeling requirements defined under the Food and Drug Regulations and Health Canada guidance.

Key labeling elements include:

  • Product name and strength
  • Drug Identification Number (DIN)
  • Active ingredients
  • Dosage form and route of administration
  • Batch or lot number
  • Expiry date
  • Manufacturer or sponsor information
  • Storage conditions
  • Directions for use and safety information

Labels must be provided in both English and French, Canada's official languages.

Barcodes may be included on pharmaceutical packaging for supply chain management and pharmacy scanning purposes, but unit level serialization is not currently mandated by Health Canada.

‍

Regulatory Timeline 

1953
Canada enacted the Food and Drugs Act, establishing the national framework for regulating pharmaceuticals and health products.

1995 onward
Health Canada introduced modern regulatory processes for drug approval and safety monitoring.

2001
Canada launched the Drug Product Database (DPD) to provide public access to approved medicines.

Ongoing
Canada continues to regulate pharmaceuticals through product authorization, quality oversight, and pharmacovigilance rather than serialization or national traceability.

Reporting Requirements 

Operation
Data to Report
When to Report
Product Authorization
Drug submission including clinical, quality, and manufacturing data
Before product approval
Drug Identification Number Assignment
Product details and formulation information
During product approval process
Establishment Licensing
Manufacturing, import, and distribution site information
Before operations begin
Adverse Reaction Reporting
Drug safety events and adverse reactions
When events occur
Product Updates
Changes to formulation, labeling, or manufacturing sites
When regulatory changes occur

Marketing authorization holders and distributors are responsible for ensuring that medicines remain compliant throughout the product lifecycle.

OperationData to ReportWhen to Report

Commission 
Aggregation 
Shipping 

GTIN, Serial, Batch, Expiry  
Parent SSCC, Child Serials  
Sender GLN, Receiver GLN, SSCC or Serial List
During packaging before shipment 
When creating cases or pallets 
Before dispatch 
ReceivingImport Clearance
Supply to Pharmacy
GTIN, Serial, Batch, Expiry  
Parent SSCC, Child Serials  
Sender GLN, Receiver GLN, SSCC or Serial List
During packaging before shipment 
When creating cases or pallets 
Before dispatch 
Returns 
Decommission 
Serial status and reference 
Reason and serials 
When return is approved 
When product is destroyed or removed 

Operational Timelines for Industry 

  • Obtain product authorization through Health Canada drug submission processes.
  • Receive a Drug Identification Number (DIN) before marketing the medicine in Canada.
  • Ensure packaging and labeling comply with bilingual labeling requirements.
  • Obtain a Drug Establishment Licence (DEL) for manufacturing, importing, or distributing medicines.
  • Maintain Good Manufacturing Practice compliance and quality systems.
  • Report adverse drug reactions through the Canada Vigilance Program.
  • Maintain distribution records and ensure compliance with Health Canada inspection requirements.

Reporting Hub

Canada does not operate a national pharmaceutical traceability reporting hub.

Regulatory oversight is managed through several Health Canada systems and databases:

Drug Identification Number (DIN) System
Every authorized medicine receives a unique DIN that identifies the product formulation, manufacturer, and therapeutic classification.

Drug Product Database (DPD)
Public database that provides information about authorized drug products in Canada.

Drug Establishment Licensing (DEL)
Ensures manufacturers, importers, distributors, and wholesalers comply with Good Manufacturing Practices.

Canada Vigilance Program
National system used for adverse drug reaction reporting and safety monitoring.

These systems support regulatory oversight but do not track serialized product movement within the supply chain.

Aggregation Requirements 

Canada does not require aggregation or serialization for pharmaceutical products.

However, many pharmaceutical manufacturers operating in Canada voluntarily implement serialization and aggregation to support global export requirements, particularly for markets such as the United States, European Union, and GCC countries that mandate serialization.

These voluntary systems typically follow GS1 standards to support supply chain automation and product verification.

Common Errors to Avoid 

  • Marketing medicines in Canada without obtaining a Drug Identification Number.
  • Failure to provide bilingual labeling in English and French.
  • Incomplete documentation during drug submission or establishment licensing.
  • Failure to maintain GMP compliance across manufacturing or distribution sites.
  • Delayed reporting of adverse drug reactions through the Canada Vigilance Program.

Trusted by Industry Leaders

Smooth and Successful

LSPedia didn’t just provide software; they ensured we were fully compliant. Anytime we had questions, the LSPedia team knew DSCSA inside and out and guided us step by step. That level of expertise made a huge difference during audits. Thanks to their expert team our audit was smooth and successful

Hussein Salman
Lead Pharmacist, Pioneer Pharmacy Services

Constant Commitment

LSPedia shows a constant commitment to improvement; whether it's their support or their product...they're always leveling up. The support team provides consistently thorough follow-up and clear, articulate communication. the support we receive represents a meaningful step up in service and is genuinely appreciated.

Zac Sweeny
EPCIS Data Encoder,Capital Wholesale Drug
Read All TestimonialsView Our Customers

Fill in the form for latest updates

Get in Touch

We invite you to learn more about how LSPedia can support your compliance and supply chain needs. For more information about our solutions, partnership opportunities, or to speak with one of our experts.

Contact Us